Key Findings from the Research:

• Cellular Performance: Osteoblasts readily attached and proliferated on NanoFUSE DBM over a 9-day period, showing comparable growth to standard tissue culture conditions.

• Enhanced Differentiation: Alkaline phosphatase activity, a key marker of early bone formation, was higher in the NanoFUSE DBM group than in groups with DBM or bioactive glass alone.

• In Vivo Bone Formation: In a mouse thigh muscle model, NanoFUSE DBM led to robust new bone formation, including the development of osteoblasts, bone marrow, and blood vessels. Bioactive glass alone showed no bone growth.

• Comprehensive Safety Profile: NanoFUSE DBM passed all biocompatibility tests (ISO 10993), showing no signs of cytotoxicity, irritation, sensitization, genotoxicity, or systemic toxicity.

The combination of DBM and bioactive glass within a gelatin-based carrier creates a moldable, osteoinductive, and osteoconductive matrix that facilitates healing throughout the defect, not just at the margins. It is a promising solution for spine surgeries, trauma, and orthopedic reconstruction, particularly in cases where autograft is not feasible.

Conclusion
 

NanoFUSE DBM represents a next-generation bone graft solution that is biologically active, clinically safe, and scientifically validated. Its dual mechanism could offer clinicians a reliable alternative to autograft with reduced patient morbidity and enhanced healing potential.